Futuredme
Tokyo, JP · 1 known investors
FuturedMe develops small-molecule drug candidates using CANDDY, a protein-degradation platform licensed from Tokyo University of Science that induces direct proteasomal degradation of disease-related proteins instead of inhibiting them. The company aims to create therapies for patients with previously undruggable targets and no existing treatment options.
BiotechDeep TechHealthtech